Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.
InnoCan Pharma's current Total Payout Yield % is -0.81%.
InnoCan Pharma Total Payout Yield % Explanation
Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.
InnoCan Pharma Total Payout Yield % Related Terms
InnoCan Pharma Total Payout Yield % Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Total Payout Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IP40 vs PG, CL, KVUE: Total Payout Yield % Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Total Payout Yield % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Total Payout Yield % distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Total Payout Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (HAM:IP40) has a Total Payout Yield % of -0.81 as of Jul. 06, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's Total Payout Yield % too high?
InnoCan Pharma's current Total Payout Yield % is -0.81. Overall, InnoCan Pharma has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Total Payout Yield % compare to PG and CL?
InnoCan Pharma's Total Payout Yield % of -0.81 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Consumer Packaged Goods company?
A good Total Payout Yield % depends on the Consumer Packaged Goods industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current Total Payout Yield % is -0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.83, compared to a current price of €1.80 — trading 77% below its estimated fair value. The current Total Payout Yield % is -0.81. InnoCan Pharma's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Total Payout Yield % is -0.81 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.80 is trading 77% below its estimated GF Value™ of €7.83.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Total Payout Yield %: -0.81
GF Value™: €7.83 vs. price of €1.80 (77% below fair value)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
63GF Score
Get the complete analysis for HAM:IP40
Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
